PubMed · 1997 · 437 citations · 19 references
Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyTumor ImmunologyAntitumor T Cell ResponsesCell-mediated ImmunityDendritic Cell BiologyEffector T Cell FunctionT Cell ActivationT Cell BiologyCytotoxic Effector FunctionDendritic Cell Antigen PresentationDendritic Cell-t Cell InteractionEffector Function AssaysT Cell Priming By Dendritic CellsT Cell Response InductionT-cell Immune ResponsesT-cell Responses To Tumor Antigens
We evaluated T-cell responses to mitogens and to defined antigens in breast cancer patients. Significant defects in responses to tetanus toxoid and influenza virus were observed in patients with advanced-stage breast cancer. To define whether these defects were associated with a defect in antigen presentation [dendritic cells (DCs)] or effector function (T cells), these cells were studied separately. Purified DCs from 32 patients with breast cancer demonstrated a significantly decreased ability to stimulate control allogeneic T cells, but stimulation of patient T cells with either control allogeneic DCs or immobilized anti-CD3 antibody resulted in normal T-cell responses, even in patients with stage IV tumors. These data suggest that reduced DC function could be one of the major causes of the observed defect in cellular immunity in patients with advanced breast cancer. We then tested whether stem cells from these patients could give rise to functional DCs after in vitro growth with granulocyte/macrophage colony-stimulating factor and interleukin 4. Normal levels of control allogeneic and tetanus toxoid-dependent T-cell proliferation were observed when DCs obtained from precursors were used as stimulators. Those cells also induced substantially higher levels of influenza virus-specific CTL responses than mature DCs from the peripheral blood of these patients, although responses did not quite reach control values. Thus, defective T-cell function in patients with advanced breast cancer can be overcome by stimulation with DCs generated from precursors, suggesting that these cells may better serve as autologous antigen carriers for cancer immunotherapy than mature peripheral blood DCs.
19
Federica Sallusto, Antonio Lanzavecchia · The Journal of Experimental Medicine · 1994 · 5.2K citations · Full text
Proliferating dendritic cell progenitors in human blood.
Nikolaus Romani, Susanne Grüner, D Brang et al. · The Journal of Experimental Medicine · 1994 · 1.9K citations · Full text
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Frank J. Hsu, Claudia Benike, Francesco Fagnoni et al. · Nature Medicine · 1996 · 1.8K citations
Medicine, Immunology, Oncology +16
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Alex Y. Huang, Paul T. Golumbek, Mojgan Ahmadzadeh et al. · Science · 1994 · 1.2K citations
Life Sciences, Immunology, Oncology +17